Another notable finding is that the favorable CV outcome benefit observed in LEADER and SUSTAIN-6 contrasts with the null results seen with other GLP-1 RA, lixisenatide, and ELIXA trial, which enrolled patients within 180 days of acute coronary syndrome or EXSCEL trial. This evidence concerns the gene GCG and acute coronary syndrome.